{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:07:39Z","timestamp":1794560859260,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibromyalgia is a complex condition characterized by widespread chronic pain, fatigue, and sleep disturbances, which significantly affect quality of life. Its pathophysiology involves central sensitization (CS) and changes in neurotransmitters. Management is challenging and requires a multidisciplinary approach that integrates pharmacological and nonpharmacological treatments. This consensus, which is based on the BASCE system, presents updated guidelines for drug and nondrug treatments. The methodology focused on the evaluation of meta-analyses and systematic reviews of the literature and on voting by experts from the Brazilian Society of Rheumatology, ensuring recommendations with at least 70% agreement. Divided into two articles, this article addresses pharmacological strategies, incorporating recent advances to optimize clinical management and promote uniformity in professional practice.<\/jats:p>","DOI":"10.1186\/s42358-025-00483-2","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:21:09Z","timestamp":1769098869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Review of fibromyalgia treatment guidelines: part 2 \u2013 pharmacological treatment"],"prefix":"10.1186","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9552-7486","authenticated-orcid":false,"given":"Roberto Ezequiel","family":"Heymann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Cruz","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo dos Santos","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Renato","family":"de Assis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"de Sousa Braz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Ranzolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Monteiro Gomides Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pimentel Fonseca Golmia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Beatriz","family":"Assad Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denison","family":"Santos Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Augusto","family":"Chiuchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Eduardo","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Roberto","family":"Provenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Maria","family":"de Freitas Trindade Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Paulo","family":"Veloso Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Ant\u00f4nio","family":"Gon\u00e7alves Pontes Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Aurelio","family":"Goldenfum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Aurelio","family":"de Freitas Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Mariti Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilton","family":"Salles Rosa Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Navarrete Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Member of the Pain Committee of the Brazilian Society of Rheumatology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"8","key":"483_CR1","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.3390\/ijms22083891","volume":"22","author":"R Siracusa","year":"2021","unstructured":"Siracusa R, Paola RD, Cuzzocrea S, Impellizzeri D. Fibromyalgia: Pathogenesis, mechanisms, diagnosis and treatment options update. Int J Mol Sci. 2021, Apr, 9;22(8):3891.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"483_CR2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/AJP.0000000000001236","volume":"40","author":"N Lahat-Birka","year":"2024","unstructured":"Lahat-Birka N, Boussi-Gross R, Ben Ari A, Efrati S, Ben-David S. Retrospective analysis of fibromyalgia: Exploring the interplay between various triggers and Fibromyalgia\u2019s severity. Clin J PAin. 2024, Oct, 1;40(10):578\u201387.","journal-title":"Clin J PAin"},{"key":"483_CR3","unstructured":"Heymann RE, et al. Brazilian consensus on the treatment of fibromyalgia. In: Rev bras reumatol. Vol. 50(1): English, Portuguese; 2010 Jan-Feb. p. 56\u201366."},{"key":"483_CR4","unstructured":"Axia.BioFarmacoeconomia e pesquisa em sa\u00fade. Available at: http:\/\/www.axiabiobrazil.com."},{"key":"483_CR5","doi-asserted-by":"crossref","unstructured":"H\u00e4user W, Wolfe F, T\u00f6lle T, U\u00e7eyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: A systematic review and meta-analysis. CNS Drugs. 26(4):297\u2013307.","DOI":"10.2165\/11598970-000000000-00000"},{"key":"483_CR6","doi-asserted-by":"crossref","unstructured":"Farag HM, Yunusa I, Goswami H, et al. Comparison of amitriptyline and US food and drug administration-approved treatments for fibromyalgia: A systematic review and network meta-analysis. JAMA Netw Open Open. 5(5):e2212939.","DOI":"10.1001\/jamanetworkopen.2022.12939"},{"issue":"2","key":"483_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/jama.2008.944","volume":"301","author":"W H\u00e4user","year":"2009","unstructured":"H\u00e4user W, Bernardy K, U\u00e7eyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA. 2009, Jan, 14;301(2):198\u2013209.","journal-title":"JAMA"},{"key":"483_CR8","doi-asserted-by":"crossref","unstructured":"Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2012;12), CD008242.","DOI":"10.1002\/14651858.CD008242.pub2"},{"key":"483_CR9","doi-asserted-by":"crossref","unstructured":"Welsch P, \u00dc\u00e7eyler N, Klose P, H\u00e4user W. Serotonin and norepinephrine reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2), CD010292.","DOI":"10.1002\/14651858.CD010292.pub2"},{"issue":"11","key":"483_CR10","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/acr.25142","volume":"75","author":"S Lederman","year":"2023","unstructured":". Lederman S, Arnold LM, Vaughn B, Kelley M, Sullivan GM. Efficacy and safety of Sublingual Cyclobenzaprine for the treatment of fibromyalgia: Results from a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (hoboken). 2023;75(11):2359\u201368.","journal-title":"Arthritis Care Res (hoboken)"},{"key":"483_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/art.20076","volume":"51","author":"JK Tofferi","year":"2004","unstructured":"Tofferi JK, Jackson JL, O\u2019Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Care Res. 2004;51:9\u201313.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"483_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF02030081","volume":"8","author":"H Vaer\u00f8y","year":"1989","unstructured":"Vaer\u00f8y H, Abrahamsen A, F\u00f8rre \u00d8, K\u00e5ss E. Treatment of fibromyalgia (fibrositis syndrome): a parallel double-blind trial with carisoprodol, paracetamol, and caffeine (somadril comp\u00ae) versus placebo. Clin rheumatol. 1989;8(2):245\u201350.","journal-title":"Clin rheumatol"},{"issue":"4","key":"483_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2147\/nedt.2006.2.4.537","volume":"2","author":"C Moret","year":"2006","unstructured":"Moret C, Briley M. Antidepressants in the treatment of fibromyalgia. Neuropsychiatr Dis Treat. 2006;2(4):537\u201348.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"483_CR14","doi-asserted-by":"crossref","unstructured":"Walitt B, Urr\u00fatia G, Nishishinya MB, Cantrell SE, H\u00e4user W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev. 2015, Jun, 5;2015(6): CD011735.","DOI":"10.1590\/1516-3180.20151335T1"},{"issue":"1","key":"483_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/s13018-023-03995-z","volume":"18","author":"BM F","year":"2023","unstructured":"F BM, Maffulli N, Eschweiler J, Baroncini A, Bell A, Colarossi G. Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis. J Orthop Surg Res. 2023, Jul, 17;18(1):504.","journal-title":"J Orthop Surg Res"},{"key":"483_CR16","unstructured":"P CW, N \u00dc, Klose P, Walitt B, H\u00e4user. Serotonin, and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018, Feb, 28;2(2): CD010292."},{"issue":"12","key":"483_CR17","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00296-018-4068-3","volume":"38","author":"AA Ottman","year":"2018","unstructured":"Ottman AA, Warner CB, Brown JN. The role of mirtazapine in patients with fibromyalgia: a systematic review. Rheumatol Int. 2018;38(12):2217\u201324.","journal-title":"Rheumatol Int"},{"key":"483_CR18","first-page":"265","volume":"49","author":"W Samborski","year":"2004","unstructured":"Samborski W, Leza\u0144ska-Szpera M, Rybakowski JK. Effects of antidepressant mirtazapine on fibromyalgia symptoms. Rocz Akad Med BialymSt. 2004;49:265\u201369.","journal-title":"Rocz Akad Med BialymSt"},{"key":"483_CR19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1345\/aph.1R725","volume":"47","author":"S Yeephu","year":"2013","unstructured":"Yeephu S, Suthisisang C, Suttiruksa S, Prateepavanich P, Limampai P, Russell IJ. Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. Ann pharmacother. 2013;47:921\u201332.","journal-title":"Ann pharmacother"},{"key":"483_CR20","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1097\/j.pain.0000000000000622","volume":"157","author":"K Miki","year":"2016","unstructured":"Miki K, Murakami M, Oka H, Onozawa K, Yoshida S, Osada K. Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain. 2016;157:2089\u201396.","journal-title":"Pain"},{"key":"483_CR21","first-page":"435","volume":"10","author":"S Suttiruksa","year":"2016","unstructured":"Suttiruksa S, Yeephu S, Prateepavanich P, Suthisisang C. Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: a double-blind, randomized, placebocontrolled trial. Asian Biomed. 2016;10:435\u201345.","journal-title":"Asian Biomed"},{"key":"483_CR22","doi-asserted-by":"crossref","unstructured":"Welsch P, Bernardy K, Derry S, Moore RA, H\u00e4user W. Mirtazapine for fibromyalgia in adults. Cochrane Database Syst Rev. 2018, Aug, 6;8(8): CD012708.","DOI":"10.1002\/14651858.CD012708.pub2"},{"key":"483_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1471-2474-12-95","volume":"12","author":"EP Calandre","year":"2011","unstructured":"Calandre EP, Morillas-Arques P, Molina-Barea R, Rodriguez-Lopez CM, Rico-Villademoros F. Trazodone plus pregabalin combination in the treatment of fibromyalgia: atwo-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet DisorD. 2011;12:95.","journal-title":"BMC Musculoskelet DisorD"},{"key":"483_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1471-2474-11-204","volume":"11","author":"P Morillas-Arques","year":"2010","unstructured":"Morillas-Arques P, Rodriguez-Lopez CM, Molina-Barea R, Rico-Villademoros F, Calandre EP. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet DisorD. 2010;11:204.","journal-title":"BMC Musculoskelet DisorD"},{"issue":"1","key":"483_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","volume":"6","author":"GJ Sills","year":"2006","unstructured":"Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108\u201313.","journal-title":"Curr Opin Pharmacol"},{"key":"483_CR26","doi-asserted-by":"crossref","unstructured":"Lyseng-Williamson KAS, MA. Pregabalin: A review of its use in fibromyalgia drugs. 2008;68:2205\u201323.","DOI":"10.2165\/00003495-200868150-00009"},{"key":"483_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jpain.2010.01.002","volume":"11","author":"W H\u00e4user","year":"2010","unstructured":"H\u00e4user W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J PAin. 2010;11:505\u201321.","journal-title":"J PAin"},{"key":"483_CR28","doi-asserted-by":"crossref","unstructured":"Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016, Sep, 29;9(9): CD011790.","DOI":"10.1002\/14651858.CD011790"},{"key":"483_CR29","doi-asserted-by":"crossref","unstructured":"Cooper TE, Derry S, Wiffen PJ, Moore RA. Gabapentin for fibromyalgia pain in adults. Cochrane pain, palliative and supportive care group, ed. Cochrane Database Syst Rev. 2017, Jan, 3;1(1): CD012188.","DOI":"10.1002\/14651858.CD012188.pub2"},{"issue":"10","key":"483_CR30","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1093\/pm\/pnaa001","volume":"21","author":"K Bruun-Plesner","year":"2020","unstructured":"Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, et al. Low-dose naltrexone for the treatment of fibromyalgia: Investigation of dose\u2012response relationships. Pain Med. 2020;21(10):2253\u201361.","journal-title":"Pain Med"},{"issue":"5","key":"483_CR31","doi-asserted-by":"publisher","first-page":"e15638","DOI":"10.1016\/j.heliyon.2023.e15638","volume":"9","author":"S Partridge","year":"2023","unstructured":"Partridge S, Quadt L, Bolton M, et al. A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia. Heliyon. 2023;9(5):e15638.","journal-title":"Heliyon"},{"key":"483_CR32","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2147\/JPR.S395457","volume":"16","author":"J Yang","year":"2023","unstructured":"Yang J, Shin KM, Do A, Bierle DM, Abu Dabrh AM, Yin Z, Bauer BA, Mohabbat AB. The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: A systematic review. J Pain Res. 2023;16:1017\u201323.","journal-title":"J Pain Res"},{"issue":"3","key":"483_CR33","first-page":"e13455","volume":"74","author":"da Rocha Ap","year":"2020","unstructured":"da Rocha Ap, Mizzaci CC, Nunes Pinto ACP, da Silva Vieira Ag, Civile V, Trevisani VFM. Tramadol for management of fibromyalgia pain and symptoms: Systematic review. Int J Clin Pract. 2020, Mar;74(3):e13455.","journal-title":"Int J Clin Pract"},{"key":"483_CR34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1533-2500.2010.00441.x","volume":"11","author":"NS Roskell","year":"2011","unstructured":"Roskell NS, Beard SM, Zhao Y, et al. A meta-analysis of pain response in the treatment of fibromyalgia. Pain Pract. 2011;11:516\u201327.","journal-title":"Pain Pract"},{"issue":"5","key":"483_CR35","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.mayocp.2016.02.002","volume":"91","author":"DL Goldenberg","year":"2016","unstructured":"Goldenberg DL, Clauw DJ, Palmer RE, Clair AG. Opioid use in fibromyalgia: a cautionary tale. Mayo Clin Proc. 2016;91(5):640\u201348.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"483_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/AJP.0000000000000079","volume":"31","author":"X Peng","year":"2015","unstructured":"Peng X, Robinson RL, Mease P, et al. Long-term evaluation of opioid treatment in fibromyalgia. Clin J PAin. 2015;31(1):7\u201313.","journal-title":"Clin J PAin"},{"issue":"10","key":"483_CR37","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.amjmed.2011.05.031","volume":"124","author":"MA Fitzcharles","year":"2011","unstructured":"Fitzcharles MA, Ste-Marie PA, Gamsa A, Ware MA, Shir Y. Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med. 2011;124(10):955\u201360.","journal-title":"Am J Med"},{"key":"483_CR38","doi-asserted-by":"publisher","first-page":"1275921","DOI":"10.3389\/fnins.2023.1275921","volume":"17","author":"JD Bao","year":"2023","unstructured":"Bao JD, Rosser MA, Park SH, Baker AK, Martucci KT. Interplay between noxious heat sensitivity and temporal summation magnitude in patients with fibromyalgia and long-term opioid use. Front neurosci. 2023;17:1275921.","journal-title":"Front neurosci"},{"key":"483_CR39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.semarthrit.2011.06.003","volume":"41","author":"E Choy","year":"2011","unstructured":"Choy E, Marshall D, Gabriel ZL, et al. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum. 2011;41:335\u201345.","journal-title":"Semin Arthritis Rheum"},{"key":"483_CR40","doi-asserted-by":"crossref","unstructured":"Derry S, Wiffen PJ, H\u00e4user W, et al. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane pain, palliative and supportive care group, ed. Cochrane Database Syst Rev. 2017, 2020, 27;3(3): CD012332.","DOI":"10.1002\/14651858.CD012332.pub2"},{"key":"483_CR41","doi-asserted-by":"crossref","unstructured":"Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Database Syst Rev. 2018, Feb, 19;2(2): CD010585.","DOI":"10.1002\/14651858.CD010585.pub2"},{"issue":"3","key":"483_CR42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1089\/acm.2020.0331","volume":"27","author":"I Kurlyandchik","year":"2021","unstructured":"Kurlyandchik I, Tiralongo E, Schloss J. Safety and efficacy of medicinal cannabis in the treatment of fibromyalgia: A systematic review. J Altern Complement Med. 2021, Mar;27(3):198\u2013213.","journal-title":"J Altern Complement Med"},{"issue":"6","key":"483_CR43","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/biomedicines11061621","volume":"11","author":"NH Strand","year":"2023","unstructured":"Strand NH, Maloney J, Kraus M, Wie C, Turkiewicz M, Gomez DA, Adeleye O, Harbell MW. Cannabis for the treatment of Fibromyalgia: A systematic review. Biomedicines. 2023, Jun, 2;11(6):1621.","journal-title":"Biomedicines"},{"issue":"4","key":"483_CR44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.14744\/nci.2023.43669","volume":"11","author":"de Carvalho Jf","year":"2024","unstructured":"de Carvalho Jf, Ribeiro MFLDS, Skare T. Cannabis therapy in rheumatological diseases: A systematic review. N Clin Istanb. 2024, Jul, 22;11(4):361\u201366.","journal-title":"N Clin Istanb"},{"issue":"8","key":"483_CR45","first-page":"e17332","volume":"13","author":"H Khurshid","year":"2021","unstructured":"Khurshid H, Qureshi IA, Jahan N, Went TR, Sultan W, Sapkota A, Alfonso M. A systematic review of fibromyalgia and recent advancements in treatment: Is medicinal cannabis a new hope? Cureus. 2021, Aug, 20;13(8):e17332.","journal-title":"Cureus"},{"issue":"7","key":"483_CR46","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/healthcare10071176","volume":"10","author":"L Nm","year":"2022","unstructured":"Nm L, Hilal FM, Bashawyah A, et al. Efficacy of acupuncture, intravenous lidocaine, and diet in the management of patients with fibromyalgia: A systematic review and network meta-analysis. Healthcare. 2022;10(7):1176.","journal-title":"Healthcare"},{"issue":"4","key":"483_CR47","doi-asserted-by":"publisher","first-page":"615","DOI":"10.5498\/wjp.v12.i4.615","volume":"12","author":"de Carvalho Jf","year":"2022","unstructured":"de Carvalho Jf, Skare TL. Lidocaine in fibromyalgia: A systematic review. World J Psychiatry. 2022;12(4):615\u201322.","journal-title":"World J Psychiatry"},{"issue":"4","key":"483_CR48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.31486\/toj.21.0038","volume":"21","author":"M Pastrak","year":"2021","unstructured":"Pastrak M, Abd-Elsayed A, Ma F, Vrooman B, Visnjevac O. Systematic review of the use of intravenous ketamine for fibromyalgia. Ochsner J. 2021;21(4):387\u201394.","journal-title":"Ochsner J"},{"issue":"1","key":"483_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s42358-024-00393-9","volume":"64","author":"B Carvalho Jf","year":"2024","unstructured":"Carvalho Jf B, Sena Ep B. Ketamine in fibromyalgia: a systematic review. Adv rheumatol. 2024;64(1):54.","journal-title":"Adv rheumatol"},{"issue":"11","key":"483_CR50","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/acr.22071","volume":"65","author":"SC Kim","year":"2013","unstructured":"Kim SC, Landon JE, Solomon DH. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. Arthritis Care Res (hoboken). 2013;65(11):1813\u201319.","journal-title":"Arthritis Care Res (hoboken)"},{"issue":"6 Suppl 63","key":"483_CR51","first-page":"S110","volume":"28","author":"M Di Franco","year":"2010","unstructured":"Di Franco M, Iannuccelli C, Atzeni F, Cazzola M, Salaffi F, Valesini G, Sarzi Puttini P. Pharmacological treatment of fibromyalgia. Clin Exp rheumatol. 2010, Nov-Dec;28(6 Suppl 63):S110\u20136.","journal-title":"Clin Exp rheumatol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-025-00483-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:58:29Z","timestamp":1781629109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-025-00483-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["483"],"URL":"https:\/\/doi.org\/10.1186\/s42358-025-00483-2","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Eduardo dos Santos Paiva and Marcos Renato Assis are co-EiC of Advances in Rheumatology. Alessandra Souza Braz and Nilton Salles Rosa Neto are Associate Editors of Advances in Rheumatology. Roberto Ezequiel Heymann is a consulting editor of Advances in Rheumatology. The peer-review of this paper was therefore overseen by an independent member of the editorial board while the submission was subject to the exact same review process as applied to any other manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}